1.
Uncomplicated skin and skin structure infections such as furuncles, minor abscesses (area of suppuration not surrounded by cellulitis/erysipelas), impetiginous lesions, superficial or limited cellulitis/erysipelas, and minor wound infections (e.g. stitch abscesses) 2.
Infections associated with, or in close proximity to, a prosthetic device 3.
Severe sepsis or septic shock 4.
Known bacteremia at time of screening 5.
Acute bacterial skin and skin structure infection (ABSSSI) due to or associated with any of the following:  Suspected or documented Gram-negative pathogens in patients with cellulitis/erysipelas or major cutaneous abscess that require an antibiotic with specific Gram-negative coverage. Patients with wound infections where Gram-negative adjunctive therapy is warranted may be enrolled if they meet the other eligibility criteria  Diabetic foot infections, gangrene, or perianal abscess  Concomitant infection at another site not including a secondary ABSSSI lesion (e.g. septic arthritis, endocarditis, osteomyelitis)  Infected burns  Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease (arterial or venous)  Any evolving necrotizing process (i.e. necrotizing fasciitis)  Infected human or animal bites. However, arthropod (e.g. insects, spiders, 'bugs') bites are allowed only if subject actually witnessed the arthropod bite through the skin in the area of the ABSSSI; these are not considered animal bites in this study  Infections at vascular catheter sites or involving thrombophlebitis  Incision surgical site infection with any of the following characteristics:
o Follows clean-contaminated surgery (urgent Use of antibiotics as follows:  Systemic antibiotic with activity against Gram-positive cocci for the treatment of any infection within 24 hours before the first infusion of study drug  Patients who failed prior therapy for the primary infection site are also excluded from enrollment  Topical antibiotic on the primary lesion within 24 hours before the first infusion of study drug except for antibiotic/antiseptic-coated dressing applied to the clean post-surgical wound 7.
Administration of linezolid within 30 days before the first infusion of the study drug 8.
Recent history of opportunistic infections where the underlying cause of these infections is still active (e.g. leukemia, transplant, acquired immunodeficiency syndrome [AIDS]) 9.
Receiving chronic systemic immunosuppressive therapy such as prednisone doses ≥20 mg per day for ≥3 of the last 12 months or therapies that in the Investigator's judgement could predispose to opportunistic infections 10. Chronic (daily for the previous 30 days) use of antipyretic medication (e.g. acetaminophen, paracetamol, non-steroidal anti-inflammatory drugs). Low-dose aspirin (≤200 mg per day) for cardiovascular prophylaxis is allowed 11. Receiving treatment for active tuberculosis 12. Last known CD4 count <200 cells/mm 3 in patients with AIDS 13. Current or anticipated neutropenia with absolute neutrophil count <1000 cells/mm 3 14. Severe renal disease defined as creatinine clearance <30 mL/min estimated by the Cockcroft-Gault formula or requirement for peritoneal dialysis, plasmapheresis, hemodialysis, venovenous dialysis, or other forms of renal filtration 15. Alanine aminotransferase or aspartate aminotransferase ≥5 upper limit of normal or moderate-to-severe hepatic disease with Child-Pugh score ≥7 defined by the following:  Presence of ascites upon examination  Evidence of encephalopathy upon examination  Total bilirubin ≥2 mg/dL  Serum albumin ≤3.5 g/dL  Prothrombin time ≥4 seconds longer than control, or international normalized ratio ≥1.7 16. Significant or life-threatening condition or organ or system condition or disease (e.g. endocarditis, meningitis, unstable CNS conditions, acidosis or history of 
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Detailed definitions of all secondary endpoints
Investigator's assessment of clinical response at 48-72-hour visit:
 Improving: improvement in the overall clinical status of the ABSSSI that was compatible with continuation of study drug therapy  Stable: signs and symptoms were stable, no apparent change in the overall clinical status of the ABSSSI that was compatible with continuation of study drug therapy  Failure: patient did not meet the requirements of 'Improving' or 'Stable' clinical response
Investigator's assessment of clinical response at Day 7 visit:
 Improving: improvement in the overall clinical status of the ABSSSI that was compatible with continuation of study drug therapy; a decrease in primary ABSSSI lesion size was assessed (area, length and width) compared with baseline; investigator assessment of tenderness was mild or absent; and no purulent drainage from a wound infection, or the purulent drainage was assessed with a lesser intensity compared with baseline/screening  Failure: patient did not meet the requirements of 'Improving' clinical response
Programmatic objective clinical response at EOT (Day 11) visit:
 Sustained clinical success was defined if a patient was afebrile (<37.7°C oral, investigator reported) or fever ≥37.7°C was attributable to a cause other than the primary ABSSSI; a decrease in primary ABSSSI lesion size was assessed (area, length and width) compared with baseline; the investigator assessment of tenderness was mild or absent; and no purulent drainage from a wound infection or the purulent drainage was assessed with a lesser intensity compared with baseline/screening. o Additionally, the patient did not receive any systemic concomitant antibiotic treatment with activity against the baseline pathogen (with the exception of aztreonam and/or metronidazole for patients with wound infection); did not have a treatment-emergent adverse event leading to discontinuation of study drug requiring additional antibiotic therapy to treat their ABSSSI; did not receive any additional antibiotic to treat the primary ABSSSI; no unplanned major surgical intervention was performed to the primary ABSSSI; did not develop osteomyelitis after baseline; for a patient with a wound infection or an abscess, no incision plus drainage was performed after Day 1 unless it was planned at randomization; for a patient with cellulitis/erysipelas, no incision plus drainage was performed after the 48-72-hour visit.
Lv X, Alder J, Li L, O'Riordan W, Rybak MJ, Ye H, Zhang R, Zhang Z, Zhu X, Wilcox MH. Efficacy and safety of tedizolid phosphate versus linezolid in a randomized Phase 3 trial in patients with acute bacterial skin and skin structure infection 5  Clinical failure was defined if a patient was febrile (≥37.7°C oral, investigator reported) and fever was attributable to the primary ABSSSI; no decrease in primary ABSSSI lesion size compared with baseline was assessed; investigator assessment of tenderness was moderate or severe, or persistent purulent drainage from a wound infection at equivalent or greater intensity compared with baseline/screening. o Moreover, the patient received systemic concomitant antibiotic treatment with activity against the baseline pathogen (with the exception of aztreonam and/or metronidazole for patients with wound infection); or had a treatment-emergent adverse event leading to discontinuation of study drug requiring additional antibiotic therapy to treat their ABSSSI; or received any additional antibiotic to treat the primary ABSSSI; or an unplanned major surgical intervention was performed to the primary ABSSSI; or developed osteomyelitis after baseline; or for a patient with a wound infection or an abscess, incision plus drainage was performed after Day 1; or for a patient with cellulitis/erysipelas, an incision plus drainage was performed after the 48-72-hour visit; or death occurred within 28 days of the first infusion of study drug.  Indeterminate response was defined if the patient had osteomyelitis at baseline; or was lost to follow-up or withdrew consent prior to EOT; or a Gram-negative pathogen was confirmed at baseline that required a different antibiotic therapy for patients with cellulitis or abscess or a different antibiotic therapy other than aztreonam and/or metronidazole for patients with wound infection.
Investigator's assessment of clinical response at EOT and post-therapy evaluation (PTE) visits:
 
